- United States
- /
- Life Sciences
- /
- NasdaqGS:SHC
Sotera Health Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Sotera Health (NASDAQ:SHC) Third Quarter 2024 Results
Key Financial Results
- Revenue: US$285.5m (up 8.5% from 3Q 2023).
- Net income: US$17.0m (up from US$13.7m loss in 3Q 2023).
- Profit margin: 6.0% (up from net loss in 3Q 2023).
- EPS: US$0.06 (up from US$0.049 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Sotera Health Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) missed analyst estimates by 40%.
Looking ahead, revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US.
Performance of the American Life Sciences industry.
The company's shares are down 3.1% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Sotera Health (at least 1 which is significant), and understanding these should be part of your investment process.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:SHC
Sotera Health
Engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally.
Reasonable growth potential and slightly overvalued.